key: cord-0692174-i5vlkqvr
authors: Kessel, Christoph; Vollenberg, Richard; Masjosthusmann, Katja; Hinze, Claas; Wittkowski, Helmut; Debaugnies, France; Nagant, Carole; Corazza, Francis; Vély, Frédéric; Kaplanski, Gilles; Girard‐Guyonvarc’h, Charlotte; Gabay, Cem; Schmidt, Hartmut; Foell, Dirk; Tepasse, Phil‐Robin
title: Discrimination of COVID‐19 from inflammation‐induced cytokine storm syndromes by disease‐related blood biomarkers
date: 2021-04-20
journal: Arthritis Rheumatol
DOI: 10.1002/art.41763
sha: 15f7cab20c4239e85b8825efffaf20e6427ba4fc
doc_id: 692174
cord_uid: i5vlkqvr

OBJECTIVES: Infection with the novel coronavirus SARS‐CoV‐2 triggers severe illness with high mortality in a subgroup of patients. Such critical course of coronavirus disease (COVID)‐19 is thought to associate with cytokine storm as in macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (sHLH), although these specific data are still lacking. In this study we aimed to directly address the question, whether immune activation in COVID‐19 does indeed mimic conditions as in these classical cytokine storm syndromes. METHODS: We quantified levels of 22 biomarkers in serum samples of COVID‐19 (n=30, n=83 longitudinal samples in total), sHLH/MAS patients (n=50) as well as healthy controls (n=9) using bead array assay as well as single‐marker ELISA and correlated results with disease outcome. RESULTS: In sHLH/MAS we observed dramatic activation of the interleukin(IL)‐18‐interferon (IFN)‐γ axis, while increased serum levels of IL‐1 receptor antagonist (IL‐1Ra), intracellular adhesion molecule 1 (ICAM‐1) and IL‐8, as well as strongly reduced levels of soluble Fas ligand (sFasL) in course of SARS‐CoV‐2 infection discriminate immune dysregulation in critical COVID‐19 from the investigated well‐recognized cytokine storm conditions. CONCLUSIONS: Serum biomarker profiles clearly separate COVID‐19 from MAS or sHLH, which questions the significance of systemic hyperinflammation following SARS‐CoV‐2 infection as well as the efficacy of drugs targeting key molecules and pathways specifically associated with systemic cytokine storm conditions in the treatment of COVID‐19.

The novel coronavirus SARS-CoV-2 is infecting ever increasing numbers of people around the globe. While the infection results in mild to moderate symptoms in most individuals, it triggers a severe illness with high mortality in a subgroup of patients.

Already early in the pandemic, severe (fatal) course of COVID-19 was proposed to correlate with hyperinflammation as seen in classic cytokine storm syndromes (1) . Those include secondary hemophagocytic lymphohistiocytosis (sHLH) which may occur, for example, in the context of infection, malignancy, metabolic disease, trauma or rheumatic disease (in the latter case referred to as macrophage activation syndrome, MAS). MAS is particularly associated with adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) in children, but is also seen in Kawasaki Disease and other rheumatic conditions. Current data suggest a strong clinical and immunophenotypic overlap between sHLH and MAS (2) .

Key molecules or pathways that drive HLH/MAS such as IL-1β, IL-6, IL-18, IFN-γ or JAK/STAT can be targeted by state-of-the-art therapies, and ever since the proposal regarding an overlap of (critical) COVID-19 with classical cytokine storm conditions has been put forward (1, 3) , those have been considered as therapeutic targets in COVID-19 or are already studied in respective clinical trials (NCT04372186, NCT04317092, NCT04324021, NCT04338958). Yet, at the same time, studies addressing the relevance of cytokine storm conditions in COVID-19 are frequently limited to discussions on IL-6(4) and draw conclusions based on comparisons with many different critical clinical conditions or even healthy controls. However, to draw such conclusions we believe it is necessary to investigate severe immunological scenarios, that are classified as "cytokine storm conditions" by respective clinical and laboratory criteria. Therefore, in this study we set out to directly compared cytokine signatures in sHLH and MAS with those in COVID-19 and describe serum biomarkers which clearly separate the different entities.

Serum samples (n=83) from COVID-19 patients (n=30) were collected at the Department of Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Germany (03-05/2020). Samples were collected ranging from hospital admission throughout the disease course. All COVID-19 patients' samples were collected during the first COVID-19 wave in Germany and none of the enrolled COVID-19 patients received

This article is protected by copyright. All rights reserved immunosuppressive or biologic therapies or (experimental) anti-viral treatment. However, patients received anti-infective drugs in cases of bacterial or fungal superinfection. Disease severity was defined as critical (presence of acute respiratory distress syndrome [ARDS] and/or deceased), severe (requiring oxygen supplementation) or moderate (neither ARDS was present nor oxygen supplementation required). ARDS was diagnosed according to the Berlin definition (bilateral opacities on chest radiograph, exclusion of other causes of respiratory failure) (5) . COVID-19 patients were categorized according to their respective worst condition over the course of hospitalization.

Included adult sHLH (n=20) and AOSD-MAS serum samples (n=17) were collected in course of previous studies (6) (7) (8) . Serum samples of pediatric/adolescent sHLH (n=4) and MAS patients (n=9) and healthy controls (n=9) were collected at University Children's Hospital Muenster, Germany. Secondary HLH and MAS samples were collected during active disease and disease classification is further detailed in the supplementary methods section as well as supplementary table S1.

All study subjects or care givers provided written informed consent. The study was approved by the already reported (6) (7) (8) Reagents and sera were prepared according to the manufacturer's instructions (R&D Systems).

Data acquisition and analysis was performed on a MAGPIX instrument (Merck Millipore, Darmstadt, Germany) using xPONENT v4.2 software (Luminex). Concentrations of S100A12 in patients' sera were quantified by sandwich ELISA using in-house monoclonal antibodies.

Serum marker data were analyzed for unsupervised clustering using correlation distance and 

This article is protected by copyright. All rights reserved Multiple spearman rank correlation analyses of serum analytes were performed and plotted using the corrplot R package and Rstudio or Graphpad Prism software (Version 8.0 for Mac OS X, Graphpad Software, La Jolla, CA, USA).

Pearson normality test using Graphpad Prism software. The large majority of data did not pass this test and were therefore subjected to non-parametric multi-comparison analyses by Kruskal Wallis followed by Dunn's multiple comparison test (Graphpad Prism v8.0). Receiver operating characteristic (ROC) curve analyses were performed using Graphpad Prism software.

In our cohort of COVID-19 patients (n=30 , table 1 

This article is protected by copyright. All rights reserved decreased in COVID-19 compared to both sHLH and MAS ( Figure 1E) . In contrast to the included COVID-19 patients, some sHLH and MAS patients received immunosuppressive medication (Table S1) . However, when removing those samples from the data set, this has only little effect on the previously recorded significances between markers reported in figure 1E ( Figure S2 ).

Over the course of the disease inflammatory biomarker levels in sera of COVID-19 patients vary with respect to sampling time point from first manifestation of symptoms ( Figure S3) . When comparing serum marker levels in the first available sample following hospitalization (days from first symptoms, median (IQR):12.5 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) ) with the respective last (31 (21-36)), we noted biomarker concentrations in some critical disease COVID-19 patients to have escalated in the disease course, while in others levels rather approached those of healthy controls ( Figure S4) . (Figure S6) . Of all tested markers, IFNγ serum levels could best separate sHLH and MAS from critical COVID-19 ( Figure 1F ; Table S2 ).

This article is protected by copyright. All rights reserved IL-18 and IFN-γ have a central role in viral defense (9) , but also in the pathogenesis of hyperinflammation as in sHLH/MAS (2) . Importantly, our serum biomarker analyses revealed a pronounced differential expression of these cytokines in SARS-COV2-induced inflammation compared to sHLH/MAS. In multiple correlation analyses in sHLH/MAS we noted a prevalence of positive associations of both IL-18 and IFN-γ with almost all quantified serum markers (Figure   2A ), which we did not observe in critical COVID-19 ( Figure 2B) and this was similarly true for many other blood biomarkers. When further analyzing associations of IL-18 with levels of IFN-γ or the IFN-γ signaling surrogates CXCL9 and CXCL10 as well as serum ferritin and thrombocyte counts, as previously established to confirm a role of IFN-γ in MAS pathogenesis(10), we noted poor correlation of these parameters in critical COVID-19 (Figure 2A, B) . Although serum ferritin levels and blood thrombocyte counts did not differ significantly between critical COVID-19 and sHLH/MAS (Figure S7) , correlation of those with other investigated parameters was strikingly different in sHLH/MAS compared to COVID-19 ( Figure 2C, D) .

The initial proposal of a cytokine storm as a relevant element of (critical) COVID-19 pathogenesis(1) intrigued physicians and researchers, particularly in the field of rheumatology, as here such conditions are seen and investigated on a regular basis(3). However, while the scientific discussion on relevance and impact of cytokine storm following SARS-COV-2 infection is still ongoing(11), to our knowledge there are yet no data which explicitly compare the immunology in COVID-19 with classical, inflammation-induced cytokine storm conditions as defined by respective clinical and laboratory criteria. Therefore, in this study we analyzed serum biomarker signatures of COVID-19 compared to sHLH and MAS as classic cytokine storm syndromes and found the IL-18-IFN-γ axis as well as levels of sFasL and ICAM-1 to clearly differentiate those from SARS-CoV-2-induced immune dysregulation.

In our patient cohort quantified inflammatory serum markers in COVID-19 increased with disease severity and could indicate disease outcome already early in the course, which supports previous data (12) . In COVID-19 with critical course, the majority of assessed biomarker levels, including IL-6, were elevated in similar range as in sHLH and MAS. Importantly, none of the enrolled COVID-19 patients received immunosuppressive or biologic therapies or (experimental) anti-viral treatment which may confound the obtained results.

In contrast to many quantified parameters, particularly the IFN-γ axis, including IL-18 as IFN-γinducing factor(9) as well as IFN-γ itself, appears deregulated in sHLH and MAS, which echoes previous data (10) . While reduced IFN-γ expression in COVID-19 has already been reported earlier(13), we now show that this as well as IL-18 significantly tells apart COVID-19 from hyperferritinemic cytokine storm conditions. While the IL-18-IFN-γ axis appears dramatically deregulated in sHLH and MAS and corresponding serum levels of these cytokines can be found in substantially increased concentration ranges compared to COVID-19, this is similarly true for serum concentrations of sFasL. However, here the differences arise from strongly decreased levels in critical COVID-19 compared to both healthy controls and sHLH or MAS patients. Decreasing sFasL-levels according to COVID-19 disease activity which phenocopy our data have been reported very recently (14) and may indicate a selective SARS-CoV-2-induced immunosuppressive effect rather than general overactivation and hyperinflammation (15) . Further, these data could point to an evasive strategy from apoptosis as previously reported for HIV on the level of FasL expression (16) .

In contrast to IL-18, IFN-γ and sFasL, serum concentrations of ICAM-1 were significantly elevated compared to both sHLH and MAS. Increased soluble ICAM-1 in COVID-19 patients' sera has already been reported earlier and is suggested to indicate excessive endothelial activation and barrier dysfunction (17) . Within our data set we observed similar changes in soluble VCAM-1, albeit those remained below significance level.

Similar to ICAM-1, IL-8 and IL-1Ra serum levels were significantly increased in particularly critical COVID-19 but not in MAS or sHLH, respectively. Elevated serum levels of these markers can indicate general inflammatory activity but with respect to the specific clinical presentation of critical disease COVID-19 patients, increased IL-8 serum concentrations may indeed reflect ARDS pathology. In ARDS patients, IL-8 has been shown to enable both neutrophil influx and survival in lung tissue (18) . Correspondingly, therapeutic efficacy of IL-8-blockade is currently tested in COVID-19 (NCT04347226).

While our analyses suggest particular inflammatory axes to contrast COVID-19 from inflammation or infection-induced cytokine storm as in MAS or sHLH, we are well aware of three limitations of our study: First, it is descriptive and limited to a rather small number of patients.

Second, even though we significantly extend beyond IL-6(4), our serum marker panel still comprises comparably few analytes, but covers those with reported relevance in classic cytokine

This article is protected by copyright. All rights reserved storm conditions (2) . Third, we enforce a comparison between serum marker signatures in clinical conditions with a predominant lung versus systemic pathology (sHLH/MAS).

Yet, despite these limitations we believe our data to provide important insights on the proposed overlap between SARS-CoV-2 induced immune dysregulation and classical cytokine storm conditions (3) and to rather question the significance of systemic hyperinflammation in COVID-19 (19) . Our analyses may further raise doubt regarding the efficacy of clinical trials targeting key molecules and pathways associated with sHLH and/or MAS in the treatment of COVID-19.

Therapeutic blockade of IFN-γ, which appears as promising therapeutic option in treating HLH (20) and potentially also MAS (21) 

COVID-19: consider cytokine storm syndromes and immunosuppression

The Immunology of Macrophage Activation Syndrome

On the Alert for Cytokine Storm: Immunopathology in COVID-19

Is a "Cytokine Storm" Relevant to COVID-19?

Acute respiratory distress syndrome: the Berlin Definition

Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect

Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients

Elevated serum levels of free interleukin-18 in adult-onset Still's disease

Immunological and inflammatory functions of the interleukin-1 family

Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

COVID-19 cytokine storm: what is in a name? Ann Rheum Dis

Accepted Article This article is protected by copyright. All rights reserved 13

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

An immunebased biomarker signature is associated with mortality in COVID-19 patients

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Fas ligand deficiency in HIV disease

Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches

Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HC: healthy control; IQR: interquartile range; MAS: macrophage activation syndrome; n.d.: not determined; SAPS: simplified acute physiology score; sHLH: secondary haemophagocytic lymphohistiocytosis Accepted Article

This article is protected by copyright. All rights reserved